gelatin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-15. Anything still debated is marked as such rather than presented as settled.
Collagen is a structural protein found in connective tissues of animals, and collagen peptides are short amino acid chains produced by hydrolyzing native collagen into smaller fragments. The hydrolysis process typically uses enzymes or acids under controlled conditions. Commercial collagen peptides often come from bovine hide, porcine skin, or fish scales. The resulting material is water-soluble and differs from intact collagen in molecular size and behavior. The term 'collagen peptide' generally refers to a mixture of peptide chains rather than a single defined molecule.
Production begins with cleaning and mincing raw collagen-rich tissues. The material undergoes pretreatment to remove non-collagenous components, followed by hydrolysis using enzymes such as pepsin or alcalase, or by acid or alkaline treatment. Reaction time, temperature, and pH influence the average molecular weight of the resulting peptides. After hydrolysis, the mixture is filtered, concentrated, and dried, often by spray drying. The final product is a powder with a characteristic amino acid profile rich in glycine, proline, and hydroxyproline.
Additional tests assess moisture, ash, and nitrogen content to confirm overall composition and processing consistency. Heavy metal analysis, including lead, arsenic, cadmium, and mercury, is performed to ensure limits are not exceeded. Microbial testing checks for total aerobic counts, yeast, mold, and specific pathogens such as Salmonella and Escherichia coli. These safety parameters are often required by regulations for food or dietary supplement ingredients. Results are compared against internal or pharmacopeial specifications, which may differ between jurisdictions.
One challenge in collagen peptide analysis is the absence of a single reference standard that covers all possible molecular weight fractions. Products from different sources or hydrolysis conditions yield different peptide profiles, complicating direct comparisons. Some laboratories use gelatin or a defined peptide mixture as a calibration standard, but this approach has limitations. Additionally, the term "collagen peptide" itself lacks a universally accepted molecular weight cutoff. Ongoing discussions aim to establish more consistent definitions and testing protocols for regulatory and research purposes.
Quality control of collagen peptides relies on methods that characterize molecular weight distribution, amino acid composition, and purity. Size exclusion chromatography (SEC) is commonly used to estimate the molecular weight profile of peptide mixtures. High-performance liquid chromatography (HPLC) can separate and quantify individual peptide fractions. Mass spectrometry provides detailed information on peptide sequences and modifications. These techniques help verify that a product meets declared specifications, though standardization across laboratories remains limited.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for spray-dried commercial grades. |
| Solubility | Soluble in water | Cold water solubility distinguishes from gelatin. |
| Typical molecular weight | 2–20 kDa | Range varies by hydrolysis conditions and source. |
| Common synonyms | Hydrolyzed collagen, collagen hydrolysate | Labeling varies by region and manufacturer. |
| Typical storage | Cool, dry conditions | Protect from moisture and heat to maintain stability. |
The functional properties of collagen peptides depend on their molecular weight profile and amino acid sequence. They are highly soluble in water and produce low-viscosity solutions even at relatively high concentrations. Some peptides exhibit surface activity, which allows them to act as emulsifiers or foaming agents in food systems. The absence of a rigid triple-helical structure distinguishes them from gelatin, which can form gels upon cooling. Chromatographic separation and mass analysis are used to characterize the peptide mixture.
Collagen peptides are short chains of amino acids derived from collagen, a structural protein found in connective tissues such as skin, bone, and cartilage. The production process involves breaking native collagen into smaller fragments through hydrolysis, which cleaves peptide bonds. Unlike intact collagen, these peptides dissolve in water and do not form a triple helix. Commercial preparations typically contain peptides with molecular weights ranging from about 2,000 to 20,000 daltons. The term collagen peptide is often used interchangeably with hydrolyzed collagen or collagen hydrolysate.
Common sources for collagen peptide production include bovine hide, porcine skin, fish skin, and poultry cartilage. The raw material is first cleaned and then treated with enzymes such as pepsin or microbial proteases under controlled conditions. Hydrolysis time, temperature, and enzyme concentration influence the final peptide size distribution. After hydrolysis, the mixture undergoes filtration, purification, and drying to yield a powder. The amino acid composition is notable for high levels of glycine, proline, and hydroxyproline, which are characteristic of collagen.
Quality control for collagen peptides includes measurements of moisture content, ash, protein content, and heavy metals. Microbial limits are set to ensure food or cosmetic grade safety, and the degree of hydrolysis serves as a key process indicator. That indicator correlates with molecular weight distribution and solubility characteristics. Regulatory requirements vary by country, and some jurisdictions restrict label claims about health effects. Documentation such as certificates of analysis and safety data sheets typically accompanies commercial shipments of the material.
Analytical testing of collagen peptides focuses on identity, purity, and molecular weight profile. Size-exclusion chromatography separates peptides by hydrodynamic volume and is often calibrated with known protein standards. Amino acid analysis after acid hydrolysis provides the compositional profile, which can confirm the collagen origin. Mass spectrometry offers detailed sequence information for individual peptides. These methods together help ensure that a product matches its specification and that batch-to-batch variability is controlled.
Commercial collagen peptides are sold as free-flowing powders that dissolve readily in water, forming clear to slightly hazy solutions. They are often classified by average molecular mass, which typically falls between 2,000 and 10,000 daltons, though products with lower or higher ranges exist. Taste is generally neutral, but some fish-derived versions may have a slight odor. Applications include food and beverage fortification, cosmetic formulations, and nutraceutical capsules. The powder is often blended with other ingredients without affecting clarity.
Collagen peptides are short chains of amino acids produced by hydrolyzing collagen extracted from animal connective tissues. The hydrolysis process breaks the native triple helix into smaller fragments, typically through enzymatic or chemical treatment. Sources include bovine hide, porcine skin, fish scales, and poultry cartilage; the resulting material is water-soluble and can be dried into a powder. Commercial production often uses controlled temperature and pH to achieve a consistent average molecular mass. The degree of hydrolysis influences the peptide size distribution and functional properties.
The amino acid profile of collagen peptides is distinctive, with glycine, proline, and hydroxyproline together accounting for a large fraction of residues. Glycine appears at nearly every third position in the original collagen sequence, a pattern partly retained in shorter peptides. Hydroxyproline is formed by post-translational modification of proline and serves as a marker for collagen-derived material. Unlike many proteins, collagen peptides contain little or no tryptophan and low levels of cysteine.
Commercial collagen peptides come from bovine hide, porcine skin, fish scales, and fish skin. Each source yields a distinct amino acid profile, including different levels of hydroxyproline and glycine. Marine sources often have lower hydroxyproline content than mammalian sources. Production involves extraction, hydrolysis, filtration, and drying, usually spray drying. The final powder is typically white to off-white and dissolves readily in water. Exact composition and peptide size depend on the raw material and the hydrolysis conditions.
Collagen is a structural protein found in skin, bone, tendon, and cartilage, where it forms a triple helix of three polypeptide chains. The chains contain repeating Gly-X-Y sequences, with proline and hydroxyproline frequently occupying the X and Y positions. Collagen peptides are fragments produced by breaking these long chains through hydrolysis. These fragments vary in length and amino acid composition depending on the source and processing method, so the term covers a range of products rather than a single defined molecule.
Hydrolysis converts native collagen into shorter peptides and improves water solubility. Enzymatic treatment with proteases such as pepsin or alkaline proteases is common, though acid or thermal hydrolysis can also be used. The resulting molecular weight distribution typically ranges from about 2 to 10 kilodaltons. Gelatin is a related product formed by partial hydrolysis, but it retains the ability to gel in water. Collagen peptides undergo further breakdown and generally do not form gels.
=== Pharmacodynamics === Most SNRIs function alongside primary metabolites and secondary metabolites in order to inhibit reuptake of serotonin, norepinepherine, and marginal amounts of dopamine. For example, venlafaxine works alongside its primary metabolite O-desmethylvenlafaxine to strongly inhibit serotonin and norepinephrine reuptake in the brain. The evidence also suggests that dopamine and norepinephrine behave in a co-transportational manner, due to the inactivation of dopamine by norepinephrine reuptake in the frontal cortex, an area of the brain largely lacking in dopamine transporters. This effect of SNRIs results in increased dopamine neurotransmission, in addition to the increases in serotonin and norepinephrine activity. Furthermore, because SNRIs are extremely selective, they have no measurable effects on other, unintended receptors, in contrast to monoamine oxidase inhibition. Pharmaceutical tests have determined that use of both SNRIs or SSRIs can generate significant anti-inflammatory action on microglia, as well.
=== Ovarian cancer and other === In 2008, the submission was announced of a registration dossier to the European Medicines Agency and the FDA for Yondelis when administered in combination with pegylated liposomal doxorubicin (Doxil, Caelyx) for the treatment of women with relapsed ovarian cancer. In 2011, Johnson & Johnson voluntarily withdrew the submission in the United States following a request by the FDA for an additional phase III study to be done in support of the submission. Trabectedin is also in phase II trials for prostate, breast, and paediatric cancers.
The industry is predominantly composed of small and medium-sized enterprises (SMEs) and is heavily concentrated geographically, with 75% of registered AI company offices located in London, the South East, and the East of England. Investment in dedicated UK AI companies reached a record £2.9 billion in 2024, driven largely by international investors. However, the sector faces a persistent "scale-up gap" for companies seeking growth capital beyond the Series A stage, as well as a critical skills shortage, particularly in technical roles and understanding AI concepts. The National AI Strategy (2021) laid out a ten-year plan to invest in the AI ecosystem, support adoption, and establish a governance framework. In 2023, the UK hosted the inaugural global AI Safety Summit, leading to the Bletchley Declaration and the establishment of the AI Security Institute (AISI) to evaluate frontier AI models. The 2025 AI Opportunities Action Plan set strategic goals to secure computing infrastructure, drive public sector adoption, and build domestic AI capabilities, supported by a £2 billion investment in AI infrastructure and the creation of "AI Growth Zones". In contrast to the European Union's comprehensive AI Act, the UK has adopted a "pro-innovation", sector-specific regulatory approach. Rather than creating a single AI regulator, the UK relies on existing bodies (such as the Competition and Markets Authority, Information Commissioner, and Financial Conduct Authority) to apply cross-cutting principles to AI systems within their domains.
== History == In 1925, construction began on the current infectious diseases hospital building (the old pavilion) and the annex building (which now houses the hospital pharmacy). On 21 September 1932, the newly completed pavilion was designated for the treatment of patients with communicable diseases, including tuberculosis (TB). Prior to the opening of the new TB pavilion in 1942, the epidemic hospital operated with 50 beds for infectious diseases and 20 beds for TB patients. These 70 beds were attended to by four nurses, a sanitary officer, a disinfectant, and two maids. The doctors who served the newly established unit were: Dimitrie Preda (1932–1959), Alfred Metz (1932–1936 and 1947–1949), Tiberiu Micle (1939–1942), Dumitru Hortopan (1940–1947), Oliver Pop (1946–1962), and Laurențiu Cucuruz (1946–1989). Alfred Metz, as a secondary physician, laid the foundations of the clinical laboratory of the newly built hospital. From 1949 to 1969, Hans Röhrich served as the head of the infectious diseases hospital, where he established the first department of thoracic and lung surgery in Timișoara. The first lung segmentectomy was performed in 1958. Starting in 1961, thoracic surgery made significant progress in areas such as thoracic plastic surgery, pneumothorax, mediastinum, rib resection, and pericardium. Virgil Ene succeeded Hans Röhrich, taking over as head of the clinic in 1970. The growing demand for hospital space prompted the construction of a new pavilion. Construction started in 1971, and the pavilion was inaugurated on 1 July 1973.
Sources: en.wikipedia.org
SR-17018, also known informally as SR-17 or just SR and as 5,6-dichloro-desmethylchlorphine, is an atypical opioid receptor modulator with unusual actions and effects. It acts as a biased partial agonist of the μ-opioid receptor (MOR), showing strong selectivity for activation of G protein signaling over β-arrestin2 recruitment at this receptor. In addition, the drug appears to also act as a MOR positive allosteric modulator, with this possibly being its primary action. Unlike conventional opioids such as morphine and fentanyl, SR-17018 produces robust analgesic effects in rodents with very little respiratory depression and with much less analgesic tolerance. Moreover, substitution of conventional opioids like morphine with SR-17018 can reverse analgesic tolerance and suppress withdrawal symptoms in rodents. However, conflicting findings exist in terms of analgesic tolerance and respiratory depression. The drug has not been formally studied in humans. SR-17018 was first described in the scientific literature by Laura Bohn and colleagues in 2017. It was encountered online as a novel designer drug by 2023. Subsequently, discussion of SR-17018 on the social media website Reddit dramatically increased in 2024. Although technically a designer opioid, SR-17018 is said to have very different effects from other opioids, for instance producing minimal euphoria. Rather than being used recreationally itself, SR-17018 is typically employed by users to prevent opioid withdrawal symptoms and facilitate opioid discontinuation in the context of opioid dependence.
== Mechanism of action == Topotecan is a semi-synthetic derivative of camptothecin. Camptothecin is a natural product extracted from the bark of the tree Camptotheca acuminata. Topoisomerase-I is a nuclear enzyme that relieves torsional strain in DNA by opening single strand breaks. Once topoisomerase-I creates a single strand break, the DNA can rotate in front of the advancing replication fork. In physiological environments, topotecan is in equilibrium with its inactive carboxylate form. Topotecan's active lactone form intercalates between DNA bases in the topoisomerase-I cleavage complex. The binding of topotecan in the cleavage complex prevents topoisomerase-I from religating the nicked DNA strand after relieving the strain. This intercalation therefore traps the topoisomerase-I in the cleavage complex bound to the DNA. When the replication-fork collides with the trapped topoisomerase-I, DNA damage occurs. The unbroken DNA strand breaks and mammalian cells cannot efficiently repair these double strand breaks. The accumulation of trapped topoisomerase-I complexes is a known response to apoptotic stimuli. This disruption prevents DNA replication and ultimately leads to cell death. This process leads to breaks in the DNA strand resulting in apoptosis. Administration of topotecan down-regulates its target, topoisomerase-I; therefore, it is dosed to maximize efficacy and minimize related toxicity. Topotecan is often given in combination with paclitaxel as first line treatment for extensive-stage small-cell lung cancer.
Antimicrobial resistance (AMR or AR) occurs when microbes evolve mechanisms that protect them from antimicrobials, which are drugs used to treat infections in humans, animals, and plants. Any microbe can develop resistance, including bacteria (antibiotic resistance), viruses (antiviral resistance), parasites (antiparasitic resistance), and fungi (antifungal resistance). Together, these adaptations fall under the AMR umbrella, posing a challenge to all countries and all demographics. Misuse and improper management of antimicrobials are primary drivers of this resistance, though it can also occur naturally through genetic mutations and the spread of resistant genes. Microbes resistant to multiple drugs are termed multidrug-resistant (MDR) and are sometimes called superbugs. Antibiotic resistance is a serious result of AMR. Resistance arises through spontaneous mutation, horizontal gene transfer, and increased selective pressure from antibiotic overuse, both in medicine and agriculture, which accelerates resistance development. Preventive measures, such as using narrow-spectrum antibiotics and improving hygiene practices, aim to reduce the spread of resistance. The World Health Organization (WHO) claims that AMR is one of the top global public health and development threats, estimating that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to over 4 million deaths in 2021. The burden of AMR is immense, with nearly 5 million annual deaths associated with resistant infections.
== Further reading == Edwards, Clive A. (ed.) Earthworm Ecology. Boca Raton: CRC Press, 2004. Second revised edition. ISBN 0-8493-1819-X Lee, Keneth E. Earthworms: Their Ecology and Relationships with Soils and Land Use. Academic Press. Sydney, 1985. ISBN 0-12-440860-5 Stewart, Amy. The Earth Moved: On the Remarkable Achievements of Earthworms. Chapel Hill, N.C.: Algonquin Books, 2004. ISBN 1-56512-337-9
== Research == A 2015 trial found nicotinamide to reduce the rate of new nonmelanoma skin cancers and actinic keratoses in a group of people at high risk for the conditions. Nicotinamide has been investigated for many additional disorders, including treatment of bullous pemphigoid and nonmelanoma skin cancers. Nicotinamide may be beneficial in treating psoriasis. There is tentative evidence for a potential role of nicotinamide in treating acne, rosacea, autoimmune blistering disorders, ageing skin, and atopic dermatitis. Nicotinamide also inhibits poly(ADP-ribose) polymerases (PARP-1), enzymes involved in the rejoining of DNA strand breaks induced by radiation or chemotherapy. ARCON (accelerated radiotherapy plus carbogen inhalation and nicotinamide) has been studied in cancer. Research has suggested nicotinamide may play a role in the treatment of HIV.
Sources: en.wikipedia.org
They are typically produced from animal connective tissues, such as bovine hide, porcine skin, or fish scales. The raw material is hydrolyzed to break down native collagen into smaller peptide chains.
Collagen peptides have a lower average molecular weight and remain soluble in cold water, whereas gelatin forms a gel when cooled. Both derive from collagen, but their processing and physical properties differ.
No, native collagen is a large, insoluble structural protein, while collagen peptides are shorter, water-soluble fragments. The hydrolysis process alters the protein's size and behavior.
Size exclusion chromatography is the most common method, often coupled with detectors such as refractive index or ultraviolet. Mass spectrometry can provide more detailed sequence information for individual peptides.